Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi
29 août 2024 14h14 HE
|
Spherix Global Insights
EXTON, PA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- The past few months have ushered in a new era of treatment for patients suffering from primary biliary cholangitis (PBC), marked by the approval of...
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
28 mars 2024 07h00 HE
|
Xilio Therapeutics, Inc.; Gilead Sciences, Inc.
-- Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers -- FOSTER CITY, Calif....
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
10 janv. 2024 07h26 HE
|
Arch Biopartners
TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from...
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
21 déc. 2023 07h01 HE
|
HOOKIPA Pharma Inc.
Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s outstanding...
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
18 oct. 2023 07h01 HE
|
HOOKIPA Pharma Inc.
HB-400, a novel arenaviral therapeutic vaccine, generates robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical settingA Gilead-led Phase 1 clinical trial to...
HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B
09 mai 2023 07h01 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, May 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine
04 janv. 2023 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
COMMUNITY EDUCATION GROUP RECEIVES 100K GRANT FOR MONKEYPOX CARE THROUGHOUT RURAL APPALACHIA
31 oct. 2022 07h11 HE
|
Community Education Group
Charleston, W. Va, Oct. 31, 2022 (GLOBE NEWSWIRE) -- CHARLESTON, W. Va. (October 31, 2022) – The Community Education Group (CEG) received a $50,000 grant from Gilead Sciences and a $50,000 grant...
Exavir Therapeutics Completes $4M Seed Financing from Key Investors
23 mai 2022 07h00 HE
|
Exavir Therapeutics
NEW YORK and OMAHA, Neb., May 23, 2022 (GLOBE NEWSWIRE) -- Exavir Therapeutics, a company dedicated to transforming the lives of people living with or at risk of acquiring HIV, today announced that...
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
19 juil. 2021 08h00 HE
|
BioNTech SE
Deal strengthens BioNTech’s cell therapy pipeline by accelerating individualized solid tumor Neoantigen TCR cell therapy research and development program and adding manufacturing footprint in North...